A Phase 1 interventional study of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-11.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand — 2 open to participants now, 4 under way, 3 of them phase 3. Hemoglobinuria, Paroxysmal · Thailand.
Among the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, this one is the 9th largest by enrollment, is the only one that started in 2015, is the only one in phase 1, and was the 1st registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →2 of the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Thailand, Brazil, Canada and 18 more countries
Ages 18+
Apellis Pharmaceuticals, Inc. · Sites in Thailand, United States, Czechia and 6 more countries
Ages 12–17
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
This study's enrollment of 23 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 83 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 6 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past.
An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of pegcetacoplan when administered to PNH patients.
This is a Phase Ib, open-label, multiple ascending dose, pilot study in patients with PNH who have not received eculizumab (Soliris)® in the past. Two cohorts of 3 subjects are planned for evaluation.
Safety will be assessed throughout the study; serial blood and urine samples will be collected for these assessments. Blood samples will be collected for the assessment of pegcetacoplan PK. Additional samples for assessment of PD will also be collected.
The study will consist of four parts;
Subjects will be entered into Part 1 of the study on Day 1 at a time designated by the PI. During Part 1, the first 3 daily SC doses of pegcetacoplan (Day 1 to 3) as well as doses on Day 8, 15 and 22 will be administered at the clinical site. From Day 4 to Day 28 daily doses of pegcetacoplan will be administered off-site by a trained study nurse at the subject's home, workplace, or other location convenient to the subject with the exception of those days where dosing is at the clinical site. Following ongoing review of available safety, PK and PD data by the investigator and sponsor, subjects showing evidence of perceived clinical benefit may progress to Part 2A and then to Part 2B of the study and continue to receive daily doses of pegcetacoplan until Day 84 and then until Day 364.
Cohort 2 will not be initiated until all subjects in Cohort 1 have reached the Day 29 visit and the SMC has reviewed emerging safety and efficacy data and determined that, at the initial dose, pegcetacoplan has an acceptable safety and tolerability profile.
The planned length of participation in the study for each subject in Cohort 2 is approximately 444 days (14.5 months) from Day 30 through completion of the Day 414 Exit visit procedures).
The study is planned to take place over approximately 24 months (from screening of Cohort 1 through completion of Cohort 2).
This time period may change in the event that the study is terminated early, additional cohorts are enrolled, additional time is required to review safety between cohorts, or extended safety and PK sampling is added for a cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
180 mg pegcetacoplan/day
Drug: Pegcetacoplan
270 mg pegcetacoplan/day
Drug: Pegcetacoplan
Complement (C3) Inhibitor
Also known as: APL-2
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
Time frame: From first dose of study drug (Day 1) up to 30 days after the last dose of study drug, up to approximately 563 days.
Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Day 365
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. LDH results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Percentage Change From Baseline in LDH at Day 365
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. LDH results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Change From Baseline in Haptoglobin at Day 365
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Haptoglobin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Percentage Change From Baseline in Haptoglobin at Day 365
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Haptoglobin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Change From Baseline in Hemoglobin at Day 365
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Hemoglobin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Percentage Change From Baseline in Hemoglobin at Day 365
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Hemoglobin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 365
The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. The FACIT-Fatigue Scale results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Day 365
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. ARC results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Percentage Change From Baseline in ARC at Day 365
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. ARC results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Change From Baseline in Total Bilirubin at Day 365
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the 3 parts of the treatment period. Total bilirubin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Mean Percentage Change From Baseline in Total Bilirubin at Day 365
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the 3 parts of the treatment period. Total bilirubin results were summarized for Cohort 2 only.
Time frame: Baseline (Day 1) and Day 365.
Number of Subjects Receiving Red Blood Cell (RBC) Transfusions
The number of on-study RBC transfusions were monitored throughout the treatment period.
Time frame: From Day 1 up to Day 533.
This Phase 1b, pilot study was conducted at 9 sites in 5 countries (Hong Kong, Malaysia, New Zealand, Thailand and United States) in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who had not received treatment with eculizumab (Soliris®) in the past, between 01 December 2015 and 26 August 2019. A total of 22 subjects were enrolled.
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 3 | 20 |
| Completed | 2 | 20 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 0 | 20 |
| Completed | 0 | 18 |
| Not completed | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 0 | 18 |
| Completed | 0 | 17 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 0 | 14 |
| Completed | 0 | 12 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 3 | 4 |
| Completed | 3 | 2 |
| Not completed | 0 | 2 |
| Withdrew: Other | 0 | 2 |
TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| All TEAEs | 2 | 18 |
| Treatment related TEAEs | 2 | 9 |
| Serious AEs | 1 | 6 |
| TEAEs leading to study drug discontinuation | 1 | 2 |
| TEAEs leading to death | 0 | 1 |
| TEAEs with mild intensity | 0 | 3 |
| TEAEs with moderate intensity | 2 | 8 |
| TEAEs with severe intensity | 0 | 5 |
| TEAEs with life threatening intensity | 0 | 1 |
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. LDH results were summarized for Cohort 2 only.
| units per liter (U/L) | Cohort 2 |
|---|---|
| Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Day 365 | -2105.2 ± 1078.79 |
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. LDH results were summarized for Cohort 2 only.
| percent change | Cohort 2 |
|---|---|
| Mean Percentage Change From Baseline in LDH at Day 365 | -84.8 ± 14.04 |
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Haptoglobin results were summarized for Cohort 2 only.
| gram per liter (g/L) | Cohort 2 |
|---|---|
| Mean Change From Baseline in Haptoglobin at Day 365 | 0.066 ± 0.1245 |
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Haptoglobin results were summarized for Cohort 2 only.
| percent change | Cohort 2 |
|---|---|
| Mean Percentage Change From Baseline in Haptoglobin at Day 365 | 166.176 ± 311.3656 |
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Hemoglobin results were summarized for Cohort 2 only.
| g/L | Cohort 2 |
|---|---|
| Mean Change From Baseline in Hemoglobin at Day 365 | 3.68 ± 2.690 |
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Hemoglobin results were summarized for Cohort 2 only.
| percent change | Cohort 2 |
|---|---|
| Mean Percentage Change From Baseline in Hemoglobin at Day 365 | 49.86 ± 43.254 |
The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. The FACIT-Fatigue Scale results were summarized for Cohort 2 only.
| score on a scale | Cohort 2 |
|---|---|
| Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 365 | 7.1 ± 11.09 |
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. ARC results were summarized for Cohort 2 only.
| 10^9 cells/L | Cohort 2 |
|---|---|
| Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Day 365 | -105.9 ± 70.28 |
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. ARC results were summarized for Cohort 2 only.
| percent change | Cohort 2 |
|---|---|
| Mean Percentage Change From Baseline in ARC at Day 365 | -47.5 ± 26.86 |
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the 3 parts of the treatment period. Total bilirubin results were summarized for Cohort 2 only.
| micromole per liter (umol/L) | Cohort 2 |
|---|---|
| Mean Change From Baseline in Total Bilirubin at Day 365 | -29.9 ± 24.34 |
Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the 3 parts of the treatment period. Total bilirubin results were summarized for Cohort 2 only.
| percent change | Cohort 2 |
|---|---|
| Mean Percentage Change From Baseline in Total Bilirubin at Day 365 | -60.9 ± 19.00 |
The number of on-study RBC transfusions were monitored throughout the treatment period.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Subjects Receiving Red Blood Cell (RBC) Transfusions | 1 | 7 |
Collected over TEAE data is reported from first dose of study drug (Day 1) up to 30 days after the last dose of study drug, up to approximately 563 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Cohort 2 | 1/20 (5%) | 6/20 (30%) | 17/20 (85%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| HypersensitivityImmune system disorders | 1/3 | 0/20 |
| HaemolysisBlood and lymphatic system disorders | 0/3 | 2/20 |
| Abdominal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/20 |
| Aplastic anaemiaBlood and lymphatic system disorders | 0/3 | 1/20 |
| Intravascular haemolysisBlood and lymphatic system disorders | 0/3 | 1/20 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 1/20 |
| Joint dislocationInjury, poisoning and procedural complications | 0/3 | 1/20 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/3 | 1/20 |
| Paroxysmal nocturnal haemoglobinuriaBlood and lymphatic system disorders | 0/3 | 1/20 |
| Cholecystitis acuteHepatobiliary disorders | 0/3 | 1/20 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| Urinary tract infectionInfections and infestations | 1/3 | 0/20 |
| Injection site erythemaGeneral disorders | 1/3 | 4/20 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 5/20 |
| HypokalaemiaMetabolism and nutrition disorders | 0/3 | 4/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 3/20 |
| Electrocardiogram QT prolongedInvestigations | 0/3 | 3/20 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 3/20 |
| PharyngitisInfections and infestations | 0/3 | 2/20 |
| PyrexiaGeneral disorders | 0/3 | 2/20 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/3 | 2/20 |
The Intent-To-Treat (ITT) population set included all subjects eligible to receive study drug and who received ≥1 dose of study drug. In this study, subjects could participate in more than 1 cohort. Overall, 2 cohorts of 22 unique subjects were evaluated as one subject participated in cohorts 1 and 2.
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 19 | 22 |
| >=65 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 1 | 9 | 10 |
| Male | 2 | 11 | 13 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| White | 3 | 1 | 4 |
| Asian | 0 | 15 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Maori | 0 | 1 | 1 |
| Other | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Not Hispanic or Latino | 3 | 19 | 22 |
| Unknown | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Aug 2019, 44 months.
Results were first posted in Jan 2021, 1 year 4 months after primary completion.
Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →